Merck Indonesia vs Pfizer Which Is Stronger?

Merck Indonesia and Pfizer are both prominent pharmaceutical companies that have been competing in the global market for decades. Merck Indonesia, a subsidiary of Merck Group, focuses on research and development in various therapeutic areas, while Pfizer is known for its wide range of medications and vaccines. Both companies have seen fluctuations in their stock prices over the years, influenced by factors such as regulatory approvals, market demand, and economic conditions. Investors often compare these two stocks to make informed decisions about their investment portfolios.

Merck Indonesia or Pfizer?

When comparing Merck Indonesia and Pfizer, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Merck Indonesia and Pfizer.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Merck Indonesia has a dividend yield of 9.17%, while Pfizer has a dividend yield of 6.4%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Merck Indonesia reports a 5-year dividend growth of 3.08% year and a payout ratio of 115.53%. On the other hand, Pfizer reports a 5-year dividend growth of 4.08% year and a payout ratio of 221.76%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Merck Indonesia P/E ratio at 12.58 and Pfizer's P/E ratio at 34.91. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Merck Indonesia P/B ratio is 2.14 while Pfizer's P/B ratio is 1.61.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Merck Indonesia has seen a 5-year revenue growth of 0.57%, while Pfizer's is 0.13%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Merck Indonesia's ROE at 16.32% and Pfizer's ROE at 4.72%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are Rp3490.00 for Merck Indonesia and $26.22 for Pfizer. Over the past year, Merck Indonesia's prices ranged from Rp3480.00 to Rp4490.00, with a yearly change of 29.02%. Pfizer's prices fluctuated between $25.20 and $31.54, with a yearly change of 25.16%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.